Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640672 | 0.93 | STK17B (0.46) | FGFR1FGFR4HDAC6P2RX7FDPS | |
| SCHEMBL27410500 | 0.92 | STK17B (0.45) | FGFR1FGFR4HDAC6P2RX7FDPS | |
| SCHEMBL4644008 | 0.91 | DRD2 (0.45) | FGFR1FGFR4HDAC6P2RX7FDPS | |
| SCHEMBL17297735 | 0.86 | PI4KA (0.55) | FGFR1DOT1L | |
| SCHEMBL17150783 | 0.85 | P2RX7 (0.45) | HDAC6P2RX7DRD2STK17BSTK17A | |
| SCHEMBL6805557 | 0.82 | P2RX7 (0.48) | FGFR1FGFR4HDAC6P2RX7FDPS | |
| SCHEMBL24669199 | 0.81 | DRD2 (0.43) | FGFR1FGFR4DOT1LDRD2STK17B | |
| SCHEMBL12049642 | 0.80 | FGFR1 (0.58) | FGFR1FGFR4HDAC6P2RX7DRD2 | |
| SCHEMBL19731262 | 0.80 | DRD2 (0.40) | DRD2STK17BSTK17APOLBMAPK1 | |
| SCHEMBL9545171 | 0.79 | P2RX7 (0.56) | FGFR1FGFR4HDAC6P2RX7FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643660-B2 | Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, method for producing polynucleotide, polynucleotide, and method for producing binding nucleic acid molecule | NEC SOLUTION INNOVATORS, LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| EP-0853084-B1 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AG (DE) | 2008-08-13 | — | — | EP | disclosed |
| CN-1495184-A | Substituted purine derivative, its preparation method, application and composition containing it | �ճ�˹�عɷݹ�˾ | 2004-05-12 | — | — | CN | disclosed |
| US-6723727-B1 | VITRONECTIN RECEPTOR ANTAGONISTS; INHIBITORS OF BONE RESORPTION; OSTEOPOROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| CN-1101816-C | Substituted purine derivatives, their preparation, their use and compositions containing them | HOECHST AG (DE) | 2003-02-19 | — | — | CN | disclosed |
| CN-1193623-A | Substituted purine derivatives, their preparation, their use and compositions containing them | HOECHST AG (DE) | 1998-09-23 | — | — | CN | disclosed |
| EP-0853084-A2 | Substituted purine derivatives as vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643660-B2 | Nucleoside derivative or salt thereof, polynucleotide synthesis reagent, method for producing polynucleotide, polynucleotide, and method for producing binding nucleic acid molecule | SNRPA1, SNRPB2, NSUN3 | FGFR1 331/4885FGFR4 1237/4885HDAC6 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.